All In Biotech

Drug Trial Radar · NCT00567489

IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients

Multi-Center, Prospective, Randomized Trial To Demonstrate Improved Metabolic Control of PEN VS Dianeal Only in Diabetic CAPD and APD Patients - The Impendia Trial

Last checked: Nov 20, 2026Latest source record: Jul 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 137 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

137

Actual

Start

Jan 2008

Primary completion

Jul 2011

Study completion Jul 2011

Sponsor

Lead sponsor
Vantive Health LLCIndustry
Sponsor type
Industry
Collaborators
Baxter Healthcare Corporation
First posted
Dec 5, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To demonstrate that use of glucose sparing prescriptions (PEN vs Dianeal only) in diabetic (Type 1 and Type 2) Continuous Ambulatory Peritoneal Dialysis (CAPD) and Automated Peritoneal Dialysis (APD)patients leads to improved metabolic control as measured by the magnitude of change from the baseline value in the HbA1c levels. Secondary Objectives: To demonstrate that use of glucose-sparing PD solutions (PEN vs Dianeal only) in diabetic (Type 1 and Type 2) CAPD and APD patients leads to lower glycemic-control medication requirements, decreased incidence of severe hypoglycemic events requiring medical intervention, improved metabolic control, nutritional status, and Quality of Life. In a subgroup of patients, the impact of glucose-sparing PD solutions (PEN vs Dianeal only) on abdominal fat and left ventricular (LV) structure and function will be assessed.

Conditions

  • ESRD
  • Diabetes
  • CAPD
  • APD

Interventions

  • PhysionealDrug

    Physioneal 40 or Physioneal 35

  • DianealDrug

    Dianeal 1.5% Dextrose (1.30% glucose), 2.5% Dextrose (2.27% glucose), 4.5% Dextrose (3.86% glucose)

  • ExtranealDrug

    7.5% Icodextrin

  • NutrinealDrug

    Amino Acids 1.1%

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From the Baseline Value in HbA1c at Month 3 and 6Time frame: Baseline, Month 3, Month 6 (End of Study)

Locations

19 sites in 5 countries. Site status is shown where the registry gives one.

  • Kwong Wah Hospital

    Kowloon, Hong Kong

  • Prince of Wales Hospital Chinese University of Hong Kong

    Shatin, N.T., Hong Kong

  • Alice Ho Miu Ling Nethersole Hospital

    Tai Po, N.T., Hong Kong

  • Moscow Clinical Hospital # 52

    Moscow, Russia

  • Moscow Hospital n a S P Botkin

    Moscow, Russia

  • Moscow Research n a M F Vladimirsky

    Moscow, Russia

  • Moscow State Medical Institution: "Municipal Clinical Hospital #7 "

    Moscow, Russia

  • St Petersburg Mariinskaya Hospital

    Saint Petersburg, Russia

  • St Petersburg St Elizabeth Hospital

    Saint Petersburg, Russia

  • Samara Hospital n a M I Kalinin

    Samara, Russia

  • National University Hospital

    Singapore, Singapore

  • Tan Tock Seng Hospital

    Singapore, Singapore

  • Kyungpook National University Hospital

    Daegu, South Korea

  • Yeungnam University Medical Center

    Daegu, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Yonsei University of Medical Center Severance Hospital

    Seoul, South Korea

  • Daegu Fatima Hospital

    Donggu, Deagu, South Korea

  • China Medical University Hospital

    Taichung, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.